Dr. R. Ananthanarayanan
Dr. R. Ananthanarayanan (Ananth) is Managing Director & Chief Executive Officer of Strides Pharma Science Limited. He has over three decades of top pedigree global pharmaceutical experience across technical and commercial functions. Before joining Strides, Ananth was President & Global Chief Operating Officer at Cipla Limited, where he oversaw the company’s generics business in regulated markets, branded generics in emerging markets, API business and complex drug-device combinations. Prior to that, he was President & CEO of Global APIs, Biologics, & Medis Generics B2B division at Teva Pharmaceutical Industries Ltd in the U.S., managing multi-billion P&L responsibility. He has also held leadership roles at Dr. Reddy’s Laboratories, Piramal Healthcare (formerly Nicholas Piramal), Galpharm International, U.K. (acquired by Perrigo Group), and Zydus Cadila. Ananth is a Graduate in Pharmaceutical Sciences and earned his Ph.D. in Pharmaceutical Technology from the University of Mumbai, India. He has also been a member of the Board of Advisors at the School of Pharmacy and Health Sciences at Fairleigh Dickinson University, New Jersey. Widely seen as a people-oriented business leader, Ananth has been a champion of the role of combining the strengths of technology and people power in driving business outcomes.